Too often, the term “closed process” is thrown around without an understanding of the salient issues. Pharmaceutical process closure can certainly provide many benefits, but there are various impacts and requirements depending on the ultimate goal and the specific process you are trying to close.
Read MoreLindsey Stigers, PE
Core Team Leader
St. Louis, MO
Lindsey Stigers has more than 18 years of experience in the design and execution of pharmaceutical and biotech projects at CRB. Most recently, she has been the project director for several large, phased expansion projects with operational pharmaceutical facilities. She provides engineering design and project management services for projects around the world.
Stigers is an associate and a business unit manager directing a multidisciplinary team focused on the pharmaceutical marketplace. Her design background includes work with a variety of processes, including active pharmaceutical ingredient manufacturing, formulation, aseptic filling, primary and secondary packaging, lyophilization, potent compounds, cytotoxic drugs, kilo labs, hydrogenation, hazardous powder handling, solvent handling, oligonucleotide synthesis, mammalian cell culture and microbial fermentation. She also has extensive experience with process simulation and data-centric project delivery.
Stigers graduated from Washington University in St. Louis with a Bachelor of Science in chemical engineering.
“I am energized by solving challenging problems, whether that is laying out a facility flow that takes the existing facility challenges and future flexibility into account or determining a way of executing work that enables the highest project team performance. I am drawn to creative and effective solutions that help our clients meet the needs of the patients they ultimately serve.”